Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022
- Saturday, September 10, 2022, 7:10
- PR Newswire
- Add a comment
Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FOLFIRI/bevacizumab in second-line KRAS-mutated mCRC Observed mDoR is supported by preclinical findings that demonstrate onvansertib in…
About the Author
admin has written 20663 stories on this site.